LuciAda — Adagrasib 200 mg, 90 pcs, Lucius

LuciAda — Adagrasib Tablets 200 mg, 90 Tablets

Product code: 502

98340₴ 107191₴ -8% On order · from 10 days

Analogues

Adakras LuciAda
1
Active ingredient
Dosage
200 mg
Dosage form Tablets
Tablets per pack 90

LuciAda is an advanced targeted antineoplastic agent belonging to the kinase inhibitor class, indicated for the treatment of non-small cell lung cancer and other solid tumors harboring the KRAS G12C mutation. The active pharmaceutical ingredient is adagrasib at a strength of 200 mg supplied as film-coated oral tablets (Adagrasib Tablets 200 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Adagrasib is a covalent inhibitor of the mutant KRAS G12C protein. KRAS mutations have long been considered "undruggable" targets in oncology. Adagrasib selectively and irreversibly binds to the KRAS G12C protein in its inactive (GDP-bound) state, blocking its ability to stimulate tumor growth, proliferation, and cancer cell survival. Adagrasib also demonstrates the ability to cross the blood-brain barrier, ensuring high clinical efficacy against brain metastases.

Supplied in a package containing 90 tablets of 200 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciAda 200 mg:

  • ✅ Innovative KRAS G12C Inhibitor: Selective and irreversible blockade of one of the most challenging mutant targets in oncology.
  • ✅ CNS Metastases Activity: Ability to cross the blood-brain barrier for intracranial tumor control.
  • ✅ Proven Clinical Efficacy: High overall response rates in previously treated NSCLC patients harboring KRAS G12C mutations.
  • ✅ Convenient Oral Dosing: Taken orally twice daily regardless of food intake.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Krazati).

LuciAda is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Adagrasib — 200 mg.
  • Excipients: Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal anhydrous silica. Coating: hypromellose, titanium dioxide, macrogol, colorants.

Packaging and Presentation: Film-coated tablets, 200 mg strength. Each package contains 90 tablets along with prescribing information. Labeled with LuciAda (Adagrasib Tablets 200 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Adagrasib is a highly selective covalent inhibitor of the mutant KRAS G12C protein. It irreversibly and selectively binds to cysteine at position 12 of the mutant KRAS G12C protein, locking it in an inactive state unable to signal cellular proliferation. This results in apoptosis and growth arrest of tumor cells harboring the KRAS G12C mutation.

Pharmacokinetics:

  • Absorption: Following oral administration, adagrasib is absorbed moderately fast. Peak plasma concentration (Tmax) is achieved within approximately 6 hours. High-fat meals may increase systemic exposure.
  • Distribution: Human plasma protein binding exceeds 98%. Adagrasib crosses the blood-brain barrier.
  • Metabolism: Extensively metabolized in the liver, primarily via cytochrome P450 enzymes (mainly CYP3A4, alongside CYP2C8 and CYP2C19).
  • Elimination: Excreted predominantly via feces (approx. 75% as metabolites and unchanged drug) and renally (approx. 4.5%). Terminal elimination half-life (T1/2) averages approximately 23 hours.

LuciAda is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer harboring a KRAS G12C mutation as determined by an approved test, who have received at least one prior systemic therapy.

LuciAda is administered orally twice daily every day approximately every 12 hours.

Dosing Regimen:
The recommended standard dose is 600 mg (three 200 mg tablets) twice daily (total daily dose of 1200 mg).

Administration Guidelines:
Tablets should be taken regardless of food intake with a glass of water. Tablets must be swallowed whole; do not break, crush, or chew. If a dose is missed or vomiting occurs after ingestion, take the next dose at the scheduled time (do not double doses to make up for a missed dose).

Administration of LuciAda is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to adagrasib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction.

Adagrasib is metabolized by CYP3A4 and acts as a modulator of specific pathways:

  • Strong CYP3A4 Inhibitors: May significantly elevate adagrasib plasma concentrations and toxicity risks. Avoid concurrent use.
  • Strong CYP3A4 Inducers: Can significantly decrease adagrasib blood concentrations and reduce antitumor efficacy. Avoid concurrent use.
  • CYP3A4, CYP2B6, and P-gp Substrates: Adagrasib may alter the metabolism and transport of co-administered drugs, warranting caution.

Pregnancy:
LuciAda is contraindicated during pregnancy. Based on its mechanism of action, adagrasib may cause fetal harm and embryotoxic toxicity when administered to pregnant women. Females of reproductive potential and male partners must utilize effective, reliable contraception during treatment and for at least 1 month following the final dose.

Lactation:
Excretion of adagrasib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Gastrointestinal Tract (Very Common): Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, stomatitis.
  • General Disorders: Fatigue, asthenia, musculoskeletal pain, dyspnea, cough.
  • Laboratory Abnormalities: Elevations in liver transaminases (ALT, AST), increased blood creatinine, anemia, lymphopenia, hypokalemia.
  • Cardiovascular System: QT interval prolongation on ECG (cardiac monitoring and electrolyte management required).

Symptoms:
Specific acute overdose symptoms of adagrasib are unestablished. Anticipated manifestations include exacerbated nausea, diarrhea, fatigue, and laboratory abnormalities.

Treatment:
No specific antidote exists. In case of overdose, discontinue adagrasib and initiate supportive and symptomatic care under vital organ monitoring.

Storage Requirements for LuciAda 200 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciAda 200 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Adagrasib Tablets 200 mg, and 90 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 15.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00